CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) indication : coronary artery disease with or without peripheral artery disease
The CADTH Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be reimbursed in combination with acetylsalicylic acid (ASA; 75 mg to 100 mg) for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in pati...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2018, November 2018
|
Edition: | Final |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be reimbursed in combination with acetylsalicylic acid (ASA; 75 mg to 100 mg) for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with concomitant coronary artery disease (CAD) and peripheral artery disease (PAD) if the following condition is met: For patients with concomitant CAD and PAD as defined in the Implementation Considerations |
---|---|
Physical Description: | 1 PDF file (7 pages) |